Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer

Endocrine-Related Cancer

Volumn 6, Issue 2, 1999, Pages 265-269

  Ingle, J N ^a   Suman, V J ^a   Jordan, V C ^b   Dowsett, M ^c  

^a MAYO CLINIC   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; AROMATASE INHIBITOR; DANAZOL; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; HUMAN; SURVIVAL TIME; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; RANDOMIZED CONTROLLED TRIALS; TAMOXIFEN; TRIAZOLES;

EID: 0032974114     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0060265     Document Type: Article

References (22)

1. Alonso-Muñoz MC, Ojeda-Gonzalez MB, Beltran-Fabregat M, Dorca-Ribugent J, Lopez-Lopez L, Borras-Balada J, Cardenal-Alemany F, Gomez-Bastiste X, Fabregat-Mayol J & Viladiu-Quemada P 1988 Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer. Oncology 45 350-353.
2. Brodie A, Lu Q, Liu Y, Long B, Wang J-P & Yue W 1998 Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Oncology 12 (Suppl 5) 36-40.
3. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A & Plourde PV 1996 Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Journal of Clinical Oncology 14 2000-2011.
4. Corkery J, Leonard RCF, Henderson IC, Gelman RS, Hourihan J, Ascoli DM & Salhanick HA 1982 Tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Research 42 3409s-3414s.
5. Dombemowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fomasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U & Trunet PF 1998 Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology 16 453-461.
6. Dowsett M, Murray RML, Pitt P & Jeffcoate SL 1986 Biochemical basis for the antagonism between aminoglutethimide and danazol in the endocrine treatment of breast cancer. Annals of Clinical Biochemistry 23 277-284.
7. Dowsett M, Pfister CU, Johnson SRD, Houston SJ, Miles DW, Verbeek JA & Smith IE. 1997a Pharmacokinetic interaction between letrozole and tamoxifen in postmenopausal patients with advanced breast cancer. Breast 6 245.
8. Dowsett M, Welch H, Blackman GM, King N, Howell A, Tobias J & Baum M 1997b A randomised, double blind, parallel-group trial to evaluate the effect of 'Arimidex' (anastrozole) on the pharmacokinetics of tamoxifen in postmenopausal breast cancer patients. Breast 6 245.
9. Goss PE & Gwyn KMEH 1994 Current perspectives on aromatase inhibitors in breast cancer. Journal of Clinical Oncology 12 2460-2470.
10. Hisamatsu K, Nomura Y & Tashiro H 1992 Aminoglutethimide and aminoglutethimide+tamoxifen. Gan to Kagaku Ryoho 19 2017-2023.
11. Ingle JN, Green SJ, Ahmann DL, Long HJ, Edmonson JH, Rubin J, Chang MN & Creagan ET 1986 Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. Journal of Clinical Oncology 4 958-964.
12. Ingle JN, Johnson PA, Suman VJ, Gerstner JB, Mailliard JA, Camoriano JK, Gesme DH Jr, Loprinzi CL, Hatfield AK & Hartmann LC 1997 A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer 80 218-224.
13. Lien EA, Anker G, Lonning PE, Solheim E & Ueland PM 1990 Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Research 50 5851-5857.
14. Lipton A, Santner SJ, Santen RJ, Harvey HA, Feil PD, White-Hersey D, Bartholomew MJ & Antle CE 1987 Aromatase activity in primary and metastatic human breast cancer. Cancer 59 779-782.
15. Lundgren S, Lonning PE, Aakvaag S & Kvinnsland S 1990 Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology 27 101-105.
16. Milsted R, Habeshaw T, Kaye S, Sangster G, Macbeth F, Campbell-Ferguson J, Smith D & Calman K 1985 A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer. Cancer Chemotherapy and Pharmacology 14 272-273.
17. Powles TJ, Ashley S, Ford HT, Gazet JC, Nash AG, Neville AM & Coombes RC 1984 Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. Lancet 1 1369-1372.
18. Rose C, Kamby C, Mouridsen HT, Bastholt L, Brincker H, Skovgaard-Poulsen H, Andersen AP, Loft H, Dombemowsky P & Andersen KW 1986 Combined endocrine treatment of postmenopausal patients with advanced breast cancer. Breast Cancer Research and Treatment 7 45-50.
19. Russell CA, Green SJ, O'Sullivan J, Hynes HE, Budd GT, Congdon JE, Martino S & Osborne CK 1997 Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. Journal of Clinical Oncology 15 2494-2501.
20. Samonis G, Margioris AN, Bafaloukos D & Razis DV 1994 Prospective randomized study of aminoglutethimide (AG) versus medroxyprogesterone acetate (MPA) versus AG+MPA in generalized breast cancer. Oncology 51 411-415.
21. Van Deijk WA, Blijham GH, Mellink WAM & Meulenberg PMM 1985 Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol. Cancer Treatment Reports 69 85-90.
22. Wander HE, Kleeberg UR, Essers U, Blossey HC & Nagel GA 1987 Aminoglutethimid plus hochdosiertes Medroxyprogesteronazetat versus Aminogluethimid plus Kortison in der Therapie des metastasierenden Mammakarzinoms. Onkologie 10 321-323.